What is an allogeneic stem cell transplant?
An allogeneic stem cell transplant replaces a person’s diseased or damaged blood-forming system with healthy stem cells from a donor. The word allogeneic means “from another person”. The donor may be a brother or sister, an unrelated volunteer found through a registry, a half-matched family member such as a parent or child, or blood from a baby’s umbilical cord.
Blood stem cells live in the bone marrow and make all the red cells, white cells and platelets the body needs. Before the transplant, the patient receives chemotherapy, sometimes with radiotherapy, called conditioning. The donor cells are then given through a drip, much like a blood transfusion. They travel to the bone marrow, settle in and begin making new blood.
What makes this transplant special is that the new immune system comes from the donor. Donor immune cells can recognise and attack leukaemia cells that survived conditioning. This is called the graft-versus-leukaemia (or graft-versus-tumour) effect, and it is one of the main reasons the treatment can cure blood cancers that chemotherapy alone cannot.
The same donor immune cells can also attack healthy tissues, causing graft-versus-host disease (GVHD). Balancing the benefits against this and other risks is at the heart of every transplant decision.
A brief history
The first successful bone marrow transplants between siblings were performed in the late 1960s and 1970s, building on decades of work on tissue typing. Large international donor registries grew in the 1980s and 1990s, making unrelated donors widely available. Gentler “reduced-intensity” conditioning, introduced around the turn of the century, opened up transplant to older people. More recently, new ways of preventing GVHD have made half-matched family donors a realistic option for most patients.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Stem cell transplant using cells from a donor |
| Main uses | Acute leukaemias, myelodysplastic syndromes, myelofibrosis and some lymphomas |
| Donor types | Matched sibling, matched unrelated, half-matched (haploidentical) family member, umbilical cord blood |
| How cells are given | Drip into a central line after conditioning chemotherapy, with or without radiotherapy |
| Hospital stay | Usually 3-6 weeks |
| Recovery | Close follow-up for at least 100 days; full recovery often takes 1-2 years |
| Main risks | Infection, graft-versus-host disease, organ damage, graft failure, relapse |
2. How it works
Three key steps
| Step | Purpose |
|---|---|
| Conditioning | Destroys remaining cancer cells and suppresses the patient’s immune system so donor cells are not rejected |
| Infusion of donor cells | Provides a new source of blood and immune cells |
| Engraftment | Donor cells settle in the marrow and start making blood, usually within 2-4 weeks |
Types of conditioning
| Type | Description | Typical patient |
|---|---|---|
| Myeloablative | High doses that wipe out the bone marrow completely | Younger, fitter people |
| Reduced-intensity | Lower doses that rely more on the donor immune effect | Older people or those with other health problems |
| Non-myeloablative | Very low doses | Selected older or frailer people |
Sources of stem cells
| Source | How it is collected | Features |
|---|---|---|
| Peripheral blood | Donor has growth factor injections, then cells are collected from the bloodstream by a machine | Most common; faster engraftment |
| Bone marrow | Taken from the donor’s hip bones under anaesthetic | Lower risk of chronic GVHD |
| Umbilical cord blood | Stored from a baby’s cord after birth | Needs less strict matching; slower engraftment |
A large trial with unrelated donors found similar two-year survival with blood or marrow stem cells. Blood stem cells lowered the risk of the graft failing, while marrow was linked to less chronic GVHD (Anasetti et al., 2012).
Tissue matching
Doctors match donors using HLA typing, a blood test of proteins on the surface of cells that the immune system uses to tell “self” from “non-self”. A brother or sister has a 1 in 4 chance of being a full match. When no sibling matches, registries of millions of volunteers are searched. People from ethnic groups that are under-represented on registries may find a full match harder to find, which is one reason haploidentical and cord blood transplants are so valuable.
3. Who it is for
Conditions treated
| Condition | When transplant is considered |
|---|---|
| Acute myeloid leukaemia | Intermediate or high-risk disease in first remission, or after relapse |
| Acute lymphoblastic leukaemia | High-risk features, persisting disease or relapse |
| Myelodysplastic syndromes | Higher-risk disease in suitable patients; the only treatment that can cure it |
| Myeloproliferative neoplasms | Higher-risk myelofibrosis |
| Chronic myelomonocytic leukaemia | Higher-risk disease in fit patients |
| Chronic myeloid leukaemia | Advanced phase or resistance to several kinase inhibitors |
| Mixed phenotype acute leukaemia | Often recommended in first remission |
| Juvenile myelomonocytic leukaemia | Main curative treatment for most children |
| Hodgkin lymphoma | Relapse after an autologous transplant |
| T-cell prolymphocytic leukaemia | To consolidate a first response in fit patients |
Weighing up the decision
Transplant is a major treatment, so doctors compare the expected benefit with the risks for each person. The European Group for Blood and Marrow Transplantation risk score combines five factors: the patient’s age, the stage of disease, the time from diagnosis, the donor type and the sex combination of donor and recipient (Gratwohl, 2012). Fitness, other illnesses and the patient’s own wishes are also taken into account.
4. Before treatment
| Step | Why it is done |
|---|---|
| HLA typing | Patient and possible family donors are tested |
| Donor search | Registries searched if no family match |
| Disease assessment | Bone marrow test to confirm remission |
| Organ function tests | Heart scan, breathing tests, kidney and liver function |
| Dental check | Treats sources of infection before immunity drops |
| Infection screening | Checks for viruses such as CMV, hepatitis and HIV |
| Fertility discussion | Conditioning often causes infertility; sperm or egg storage may be possible |
| Central line | A tube placed in a large vein for drips and blood tests |
| Carer planning | A carer is usually needed for several months after discharge |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Admission | Usually a few days before the transplant |
| 2. Conditioning | Chemotherapy, sometimes with total body irradiation, over about 2-7 days |
| 3. Day 0 | Donor cells are given through the central line over about an hour |
| 4. Low count period | For 2-4 weeks, blood counts are very low; transfusions and antibiotics are often needed |
| 5. Engraftment | White cells start to recover |
| 6. Discharge | Home or nearby accommodation when counts and eating have recovered |
| 7. Early follow-up | Clinic visits once or twice a week for the first 100 days |
| 8. Long-term follow-up | Less frequent visits for life |
Medicines after transplant
Most people take medicines to prevent GVHD, such as ciclosporin or tacrolimus, often with methotrexate or other drugs. Many centres now give post-transplant cyclophosphamide, a few days after the infusion, to reduce GVHD, particularly with half-matched donors. Antiviral, antifungal and antibiotic tablets protect against infection while the new immune system develops.
6. Side effects and risks
| Risk | What it involves |
|---|---|
| Infection | Bacterial, viral and fungal infections; reactivation of viruses such as CMV |
| Acute GVHD | Usually in the first months; rash, diarrhoea or liver problems |
| Chronic GVHD | Later; dry eyes and mouth, skin tightening, lung or joint problems |
| Mouth sores (mucositis) | From conditioning; may need strong pain relief and tube feeding |
| Nausea, diarrhoea and hair loss | From conditioning |
| Graft failure | Donor cells do not take or are lost |
| Organ damage | Liver, kidney, lung or heart problems |
| Infertility | Common after myeloablative conditioning |
| Relapse | The original disease can return |
| Late effects | Cataracts, hormone problems, bone thinning, second cancers |
Graft-versus-host disease
GVHD happens when donor immune cells attack the patient’s tissues, most often the skin, gut and liver. It is prevented with immune-suppressing medicines and treated, when it occurs, mainly with steroids. A review of acute GVHD describes how damage from conditioning triggers inflammation that activates donor T cells (Zeiser and Blazar, 2017).
For people whose GVHD does not respond to steroids, newer drugs such as ruxolitinib are now available. Mild GVHD may be linked with a stronger effect against leukaemia, so doctors aim to control it rather than eliminate every trace.
7. Results and outlook
| Evidence | Main finding |
|---|---|
| Randomised trial of blood vs marrow stem cells from unrelated donors (551 people) | Two-year survival was about half in both groups (51% vs 46%), with less graft failure using blood stem cells and less chronic GVHD using marrow (Anasetti et al., 2012) |
| EBMT risk score | Survival is consistently better in younger people transplanted early in their disease with a well-matched donor (Gratwohl, 2012) |
| Review of stem cell transplantation | Describes how transplant offers cure for many blood cancers through both high-dose therapy and the donor immune effect (Copelan, 2006) |
Results depend greatly on the disease, its stage, the patient’s age and fitness, and the donor. People transplanted in first remission generally do better than those transplanted with active disease. Your team can give you figures that apply to your situation.
8. Recovery and aftercare
The first 100 days
| Tip | Why |
|---|---|
| Stay close to the transplant centre | Frequent visits and quick access if problems arise |
| Take every medicine as prescribed | Immune-suppressing and anti-infection drugs are vital |
| Report fever straight away | Infection can become serious quickly |
| Follow food safety advice | Reduces the risk of food-borne infection |
| Avoid crowds and people who are unwell | Your immune system is still weak |
| Check your skin, gut and eyes | Early GVHD is easier to treat |
Longer-term recovery
| Area | What to expect |
|---|---|
| Energy | Tiredness can last for months; gradual exercise helps |
| Vaccinations | Childhood vaccines are repeated, starting from several months after transplant |
| Work and school | Many people return within 6-12 months, sometimes longer |
| Emotional health | Anxiety and low mood are common; support is available |
| Survivorship clinic | Screening for late effects such as hormone, bone, heart and skin problems |
Relapse after transplant
If the disease returns, options may include stopping immune-suppressing drugs to boost the donor effect, an infusion of extra donor immune cells (donor lymphocyte infusion), targeted drugs, or occasionally a second transplant.
Caring for someone after transplant
Carers play a central role, especially in the first few months. Tasks can include giving medicines, spotting warning signs, preparing safe food and travelling to appointments. Transplant teams usually run carer education sessions, and it is important for carers to look after their own health and seek support.
Being a donor
Donors are carefully checked to make sure donation is safe for them. Blood stem cell donation feels similar to giving blood but takes several hours, after a few days of growth factor injections that can cause bone aches. Marrow donation needs a short anaesthetic and causes soreness in the hips for a few days. Most donors recover quickly.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Autologous stem cell transplant | Uses the patient’s own cells; for myeloma and some lymphomas, but has no donor immune effect |
| CAR-T cell therapy | Some relapsed lymphomas and B-cell ALL |
| Chemotherapy alone | Lower-risk leukaemias |
| Targeted drugs or low-intensity treatment | People not fit for transplant |
| Clinical trials | New conditioning and GVHD prevention approaches |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is the transplant an operation? | No, the cells are given through a drip |
| Will my blood group change? | It may change to the donor’s blood group |
| Can I meet my donor? | Rules vary by country; contact may be possible after a set time |
| What if no matched donor is found? | Half-matched family donors or cord blood are often used |
| Will I be able to have children? | Fertility is often affected; ask about storing sperm or eggs beforehand |
| When can I drive or travel? | Usually after several months; check with your team |
| How long until my immune system recovers? | Often 1-2 years |
11. Questions to ask your care team
- Why do you recommend a transplant for me, and what are the alternatives?
- What kind of donor do you plan to use?
- What type of conditioning will I have?
- What are my chances of cure, relapse and serious complications?
- How long will I be in hospital, and how far from the centre can I live afterwards?
- Who can be my carer, and what will they need to do?
- How will my fertility be affected?
Resources
- Anasetti, C. et al. (2012) ‘Peripheral-blood stem cells versus bone marrow from unrelated donors’, New England Journal of Medicine, 367(16), pp. 1487-1496.
- Copelan, E.A. (2006) ‘Hematopoietic stem-cell transplantation’, New England Journal of Medicine, 354(17), pp. 1813-1826.
- Gratwohl, A. (2012) ‘The EBMT risk score’, Bone Marrow Transplantation, 47(6), pp. 749-756.
- Zeiser, R. and Blazar, B.R. (2017) ‘Acute graft-versus-host disease – biologic process, prevention, and therapy’, New England Journal of Medicine, 377(22), pp. 2167-2179.
- National Cancer Institute (2026) Stem Cell and Bone Marrow Transplants for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant (Accessed: October 2026).
- National Cancer Institute (2026) Acute Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.